KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Fulgent Genetics (FLGT) Accumulated Depreciation & Amortization (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $57.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 12.06% to $57.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.9 million through Dec 2025, up 12.06% year-over-year, with the annual reading at $57.9 million for FY2025, 12.06% up from the prior year.
  • Accumulated Depreciation & Amortization hit $57.9 million in Q4 2025 for Fulgent Genetics, up from $54.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $115.9 million in Q4 2022 to a low of $12.8 million in Q1 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $44.1 million across 5 years, with a median of $46.9 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 490.41% in 2022 and later plummeted 55.45% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $19.6 million in 2021, then soared by 490.41% to $115.9 million in 2022, then tumbled by 55.45% to $51.6 million in 2023, then rose by 0.15% to $51.7 million in 2024, then increased by 12.06% to $57.9 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for FLGT at $57.9 million in Q4 2025, $54.2 million in Q3 2025, and $58.7 million in Q2 2025.